Management of late-life psychosis

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 3, 1996, Pages 39-45

  Jeste, Dilip V ^a   Eastham, John H ^a   Lacro, Jonathan P ^a   Gierz, Monika ^b   Field, Martin G ^c   Harris, M Jackuelyn ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c Edgemoor Geriatric Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN ANTAGONIST; SERTINDOLE; ZIPRASIDONE;

AGING; AGRANULOCYTOSIS; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONFUSION; DOSE RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; LETHARGY; MAINTENANCE THERAPY; ONSET AGE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SOMNOLENCE; TARDIVE DYSKINESIA;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA;

EID: 0030013174     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
2. Harris MJ, Jeste DV. Late-onset schizophrenia: an overview. Schizophr Bull 1988;14:39-55
3. Jeste DV, Harris MJ, Krull A, et al. Clinical and neuropsychological characteristics of patients with late-onset schizophrenia. Am J Psychiatry 1995;152:722-730
4. Corey-Bloom J, Jernigan T, Archibald S, et al. Quantitative magnetic resonance imaging in late-life schizophrenia. Am J Psychiatry 1995;152: 447-449
5. Andreasen NC, Amdt S, Swayze VI, et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994;266:294-298
6. Belitsky R, McGlashan TH. At issue: the manifestations of schizophrenia in late life: a dearth of data. Schizophr Bull 1993;19:683-685
7. Nasar S. The lost years of a Nobel laureate. The New York Times, November 13, 1994
8. Jeste DV, Lacro JP, Gilbert PL, et al. Treatment of late-life schizophrenia with neuroleplics. Schizophr Bull 1993;19:817-830
9. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(4):52S-56S
10. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 1995;52:756-765
11. Schooler N, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487
12. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:173-188
13. Jeste DV, Gilbert PL, McAdams LA, et al. Considering neuroleptic maintenance and taper on a continuum: need for individual rather than dogmatic approach. Arch Gen Psychiatry 1995;52:209-212
14. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992;4:187-195
15. Hamot HG, Patin RJ, Singer MJ. Factor structure of the Sandoz Clinical Assessment Geriatric (SCAG) scale. Psychopharmacol Bull 1984;20: 142-150
16. Honigfeld G. NOSIE-30: history and current status of its use in pharmacophychiatric research. In: Pichot P, ed. Modem Problems of Pharmacopsychiatry, 7: Psychological Measurements in Psychopharmacology, Basel, Switzerland: Karger; 1974:238-263
17. Frankenburg FR, Kalunian D. Clozapine in the elderly. J Geriatr Psychiatry Neurol 1994;7:129-132
18. Chengappa KNR, Baker RW, Kreinbrook SB, et al. Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatry Neurol 1995;8: 12-15
19. Pitner JK, Mintzer JE, Pennypacker LC, et al. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995; 56:180-185
20. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. American Journal of Geriatric Psychiatry 1995;3:26-33
21. Pinter MM, Helscher RJ. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995;5:135-146
22. Lew MF, Waters CH. Clozapine treatment of Parkinsonism with psychosis. J Am Geriatr Soc 1993;41:669-671
23. Factor SA, Brown D, Molho ES, et al. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994;44: 544-546
24. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
25. Borison RL, Davidson M, Berman I. Risperidone treatment in elderly patients with schizophrenia or dementia [poster]. Presented at the American Psychiatric Association 46th Institute of Hospital and Community Psychiatry; Sept 30-Oct 4,1994; San Diego, Calif
26. Allen RL, Walker Z, D'Ath PJ, et al. Risperidone for psychotic and behavioral symptoms in Lewy body dementia [letter]. Lancet 1995;346:185
27. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987;48(5, suppl):9-15
28. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994;343:1370-1371
29. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
30. Howard R, Levy R. Charles Bonnet syndrome plus: complex visual hallucinations of Charles Bonnet syndrome type in late paraphrenia. International Journal of Geriatric Psychiatry 1994;9:399-404
31. Berman I, Merson A, Allan E, et al. Effect of risperidone on cognitive performance in elderly schizophrenic patients: a double-blind comparison with haloperidol [abstract]. Presented at the 35th annual meeting of the New Clinical Drug Evaluation Unit; May 31-June 3, 1995; Orlando, Fla; poster no. 93
32. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
33. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
34. Jeste DV, Eastham JH, Gierz M, et al. Use of risperidone in the elderly. In: Ayd FJ, ed. The Art of Rational Risperidone Therapy. Baltimore, Md: Ayd Medical Communications. In press
35. Andreasen NC. The Scale for the Assessment of Positive Symptoms in Schizophrenia (SAPS). Iowa City, Iowa: University of Iowa; 1983
36. Andreasen NC, Olsen S. Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982;39:789-794
37. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982;39:784-788
38. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
39. Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
40. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(suppl 212):11-19